Brokerages Expect Danaher Corporation (DHR) Will Post Quarterly Sales of $4.95 Billion
Equities analysts expect Danaher Corporation (NYSE:DHR) to report $4.95 billion in sales for the current fiscal quarter, Zacks reports. Eight analysts have issued estimates for Danaher Corporation’s earnings. The lowest sales estimate is $4.91 billion and the highest is $5.00 billion. Danaher Corporation posted sales of $4.58 billion during the same quarter last year, which suggests a positive year-over-year growth rate of 8.1%. The company is expected to issue its next quarterly earnings report on Tuesday, January 30th.
On average, analysts expect that Danaher Corporation will report full-year sales of $4.95 billion for the current year, with estimates ranging from $18.15 billion to $18.25 billion. For the next fiscal year, analysts anticipate that the company will report sales of $18.99 billion per share, with estimates ranging from $18.83 billion to $19.17 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that follow Danaher Corporation.
Danaher Corporation (NYSE:DHR) last announced its quarterly earnings data on Thursday, October 19th. The conglomerate reported $1.00 earnings per share for the quarter, beating analysts’ consensus estimates of $0.95 by $0.05. Danaher Corporation had a net margin of 13.36% and a return on equity of 11.29%. The company had revenue of $4.53 billion during the quarter, compared to analyst estimates of $4.47 billion. During the same quarter last year, the business posted $0.87 EPS. The firm’s revenue for the quarter was up 9.6% on a year-over-year basis.
A number of equities research analysts recently weighed in on DHR shares. Citigroup Inc. set a $96.00 price objective on shares of Danaher Corporation and gave the company a “buy” rating in a report on Friday, July 21st. Wells Fargo & Company reiterated a “market perform” rating on shares of Danaher Corporation in a report on Saturday, July 22nd. BidaskClub lowered shares of Danaher Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, July 25th. Zacks Investment Research lowered shares of Danaher Corporation from a “buy” rating to a “hold” rating in a report on Thursday, July 27th. Finally, Jefferies Group LLC reiterated a “buy” rating and set a $95.00 price objective on shares of Danaher Corporation in a report on Friday, August 4th. One analyst has rated the stock with a sell rating, four have given a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. Danaher Corporation currently has an average rating of “Buy” and an average price target of $93.31.
Shares of Danaher Corporation (DHR) traded down $0.28 on Tuesday, reaching $93.30. 1,510,518 shares of the company were exchanged, compared to its average volume of 2,668,045. Danaher Corporation has a one year low of $76.27 and a one year high of $93.86. The company has a market cap of $65,090.00, a price-to-earnings ratio of 23.96, a price-to-earnings-growth ratio of 2.22 and a beta of 1.02. The company has a quick ratio of 1.00, a current ratio of 1.43 and a debt-to-equity ratio of 0.42.
The company also recently disclosed a quarterly dividend, which was paid on Friday, October 27th. Stockholders of record on Friday, September 29th were given a $0.14 dividend. This represents a $0.56 dividend on an annualized basis and a dividend yield of 0.60%. The ex-dividend date of this dividend was Thursday, September 28th. Danaher Corporation’s payout ratio is currently 16.67%.
In other news, insider William King sold 43,688 shares of Danaher Corporation stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $82.86, for a total value of $3,619,987.68. Following the transaction, the insider now owns 45,748 shares of the company’s stock, valued at approximately $3,790,679.28. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CAO Robert S. Lutz sold 11,189 shares of Danaher Corporation stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $91.66, for a total transaction of $1,025,583.74. Following the completion of the transaction, the chief accounting officer now directly owns 18,314 shares in the company, valued at approximately $1,678,661.24. The disclosure for this sale can be found here. In the last ninety days, insiders sold 317,498 shares of company stock worth $28,838,801. Insiders own 12.20% of the company’s stock.
Large investors have recently added to or reduced their stakes in the business. GQG Partners LLC purchased a new stake in Danaher Corporation during the 2nd quarter worth approximately $101,000. Proficio Capital Partners LLC grew its position in Danaher Corporation by 92.3% during the 1st quarter. Proficio Capital Partners LLC now owns 1,246 shares of the conglomerate’s stock worth $105,000 after purchasing an additional 598 shares during the last quarter. Zions Bancorporation grew its position in Danaher Corporation by 118.3% during the 3rd quarter. Zions Bancorporation now owns 1,231 shares of the conglomerate’s stock worth $106,000 after purchasing an additional 667 shares during the last quarter. Patten Group Inc. grew its position in Danaher Corporation by 262.3% during the 3rd quarter. Patten Group Inc. now owns 4,830 shares of the conglomerate’s stock worth $114,000 after purchasing an additional 3,497 shares during the last quarter. Finally, Monetary Management Group Inc. grew its position in Danaher Corporation by 10.7% during the 2nd quarter. Monetary Management Group Inc. now owns 1,550 shares of the conglomerate’s stock worth $131,000 after purchasing an additional 150 shares during the last quarter. 75.38% of the stock is currently owned by institutional investors.
About Danaher Corporation
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with MarketBeat.com's FREE daily email newsletter.